Tumor radioimmunolocalization in nude mice by mono- and divalent- single-chain Fv antiplacental alkaline phosphatase antibodies

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 1, 2007, Pages 64-72

  Sheikholvaezin, Ali ^a   Eriksson, David ^a   Åhlström, Katrine Riklund ^a   Johansson, Lennart ^a   Stigbrand, Torgny ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

PLAP; Radioimmunolocalization; Recombinant antibody; Tumor targeting

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; PLACENTA ALKALINE PHOSPHATASE ANTIBODY; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY COMBINING SITE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG RETENTION; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SCINTIGRAPHY; TUMOR; TUMOR GROWTH; TUMOR LOCALIZATION;

ALKALINE PHOSPHATASE; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; PLACENTA; RADIOIMMUNODETECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34247897187     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.340     Document Type: Article

References (47)

1. Stockwin LH, Holmes S. Antibodies as therapeutic agents: Vive la renaissance! Exp Opin Biolo Ther 2003;3:1133.
2. Koppe MJ PE, Aarts F, Oyen Wj, et al. Antibody-guided radiation therapy of cancer. Cancer Metast Rev 2005;24:539-67.
3. Wu AM, Senter PD. Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137.
4. Pohlman B, Sweetenham J, Macklis RM. Review of clinical radioimmunotherapy. Exp Rev Anticancer Ther 2006;6:445.
5. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004;5:292.
6. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002;43:693.
7. Stigbrand T, Hietala SO, Johansson B, et al. Tumour radioimmunolocalization in nude mice by use of antiplacental alkaline phosphatase monoclonal antibodies. Tumour Biol 1989;10:243.
8. Kosmas CK, Hird V, and Epenetos AA. Monoclonal antibody targeting of ovarian carcinoma. Oncology 1998;55:435.
9. Albrecht H, DeNardo SJ. Recombinant antibodies: From the laboratory to the clinic. Cancer Biother Radiopharm 2006;21:285.
10. Wu AM, Yazaki PJ: Designer genes: Recombinant antibody fragments for biological imaging. Q J Nucl Med 2000;44:268.
11. Adams GP, McCartney JE, Tai MS, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993;53:4026.
12. Hu S, Shively L, Raubitschek A, et al. Minibody: A novel engineered anticarcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56:3055.
13. Deonarain MP, Rowlinson-Busza G, George AJ, et al. Redesigned antihuman placental alkaline phosphatase single-chain Fv. Soluble expression, characterization and in vivo tumour targeting. Protein Eng 1997;10:89.
14. Borsi L, Balza E, Bestagnb M, et al. Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002;102:75.
15. Yazaki PJ, Wu AM, Tsai SW, et al. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and 184.66 minibody: Comparison to radioiodinated fragments. Bioconjug Chem 2001;12:220.
16. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific, small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44:1962.
17. 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res 2004;10:5014.
18. Adams GP, Tai MS, McCartney JE, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 2006;12:1599.
19. Wu AM, Chen W, Raubitschek A, et al. Tumor localization of anti-CEA single-chain Fvs: Improved targeting by noncovalent dimers. Immunotechnology 1996;2:21.
20. Millan J. Mammalian alkaline phosphatases. From Biology to Applications in Medicine and Biotechnology. Weinheim, Germany. Wiley-Vch, 2006:25.
21. Hirano KD, Yamamoto UM, Brehmer-Andersson H, et al. Levels of alkaline phosphatase isozymes in human seminoma tissue. Cancer Res 1987;47:2543.
22. Millan J. Mammalian alkaline phosphatases. From Biology to Applications in Medicine and Biotechnology. Weinheim, Germany: Wiley-Vch, 2006:187.
23. Eriksson D, Jomani HM, Sheikholvaezin A, et al. Combined low dose radio- and radioimmunotherapy of experimental HeLa Hep 2 tumours. Eur J Nucl Med Mol Imag 2003;30:895.
24. Riklund KU, Makiya A, Sundstrom R, et al. Radioimmunotherapy of HeLa cell tumors in nude mice by a combination of I 131-labeled monoclonal antibodies against placental alkaline phosphatase and cytokeratin. Tumor Targ 1995;1:239.
25. Sheikholvaezin A, Sandström P, Eriksson D, et al. Optimizing the generation of recombinant single-chain antibodies against placental alkaline phosphatase. Hybridoma 2006;25:181.
26. Sheikholvaezin A, Eriksson D, Riklund K, et al. Construction and purification of a covalently linked divalent tandem scFv antibody against placental alkaline phosphatase. Hybridoma 2006;25:255.
27. Moore AE, Sabachewsky I, Toolan HW. Culture characteristics of four permanent lines of human cancer cells. Cancer Res 1955;15:598.
28. Millan JL, Stigbrand T. Antigenic determinants of human placental and testicular placental-like alkaline phosphatases as mapped by monoclonal antibodies. Eur J Biochem 1983;136:1.
29. Orlandi R, Gussow DH, Jones PT, et al. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci U S A 1989;86:3833.
30. Desplancq D, King DJ, Lawson AD, et al. Multimerization behaviour of single-chain Fv variants for the tumour-binding antibody, B72.3. Protein Eng 1994;7:1027.
31. Pluckthun A, Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 1997;3:83.
32. Hunter WM, Greenwood FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 1962;194:495.
33. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001;61:4750.
34. Buchsbaum DJ. Experimental radioimmunotherapy. Semin Radiat Oncol 2000;10:156.
35. Reff ME, Heard C. A review of modifications to recombinant antibodies: Attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol 2001;40:25.
36. Kortt AA, Dolezal O, Power BE, et al. Dimeric and trimeric antibodies: High avidity scFvs for cancer targeting. Biomol Eng 2001;18:95.
37. Milenic DE, Yokota T, Filpula DR, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991;51:6363.
38. King DJ, Turner A, Farnsworth AP, et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 1994;54:6176.
39. Olafsen T, Cheung CW, Yazaki PJ, et al. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel 2004;17:21.
40. Huang BC, Davern S, Kennel SJ. Mono and bivalent binding of a scFv and covalent diabody to murine laminin-1 using radioiodinated proteins and SPR measurements: Effects on tissue retention in vivo. J Immunol Meth 2006;313:149.
41. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003;9:571.
42. Viti F, Tarli G, Giovannoni L, et al. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 1999;59:347.
43. Adams GP, Schier R, McCall AM, et al. Prolonged in vivo tumour retention of a human diabody, targeting the extracellular domain of human HER2/neu. Br J Cancer 1998;77:1405.
44. Wittel UA, Jain M, Goel A, et al. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Nucl Med Biol 2005;32:157.
45. Beresford GW, Pavlinkova G, Booth BJ, et al. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody. Int J Cancer 1999;81:911.
46. Goel A, Beresford GW, Colcher D, et al. Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: Expression, purification, and characterization. J Biochem (Tokyo) 2000;127:829.
47. Huang BC, Foote LJ, Lankford TK, et al. A diabody that dissociates to monomer forms at low concentration: Effects on binding activity and tumor targeting. Biochem Biophys Res Commun 2005;327:999.